Study of a new drug for GBA-related Parkinson’s
Part of Brain & nervous system, Genetic & congenital, Hormones & metabolism clinical trials.
This study is looking for ways to find new drugs that may help people with Parkinson’s caused by changes in the GBA gene. It may also include people with Gaucher disease and healthy volunteers, using blood and possibly skin samples.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years old or older.
- Have Parkinson’s disease, Gaucher disease, or be a healthy control volunteer.
- Be able to give written consent (unless you can’t physically sign).
- If you need skin samples: you must not have a history of keloids, bleeding/clotting problems, anesthesia allergy, or certain blood-thinning medicines that make sampling unsafe.
- If you need blood samples: you must not have bleeding/clotting problems or other conditions that make blood draws too risky.
- You must agree to follow the study and clinic safety rules, including avoiding refusals to required precautions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how standard treatments for Gaucher disease affect lung problems, bone damage, and parkinson-like symptoms. It aims to find better ways to treat these complications and improve quality of life.
This study looks at people with Parkinson’s who carry a specific genetic change in the GBA gene. It uses several tests (including brain scans) to understand the disease better and may help guide future treatments.
This study looks at early (before full disease) Parkinson-like symptoms in people who carry a specific genetic change called GBA1. It may help researchers understand who could develop Parkinson’s and how early signs can be tracked.
This study looks at non-motor symptoms (like mood, thinking, or sleep problems) in people with a specific genetic change linked to Parkinson's disease. It compares those with the GBA gene change to those without it to see how symptoms differ.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This study aims to understand genetic factors in lysosomal storage disorders—rare conditions where the body cannot break down certain substances. Researchers will collect information from patients with these disorders, their family members, and healthy volunteers to learn how these diseases develop and affect people over time.
Hear when a new Gaucher Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.